AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Primary Immune Deficiency (PID) Therapeutics Pipeline Review, H1 2019 Edition - ResearchAndMarkets.com

April 8, 2019

DUBLIN--(BUSINESS WIRE)--Apr 8, 2019--The “Primary Immune Deficiency (PID) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Primary Immune Deficiency (PID) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 8, 3, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 8, 1 and 5 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Key Topics Covered:

  1. Introduction
  2. Primary Immune Deficiency (PID) - Overview
  3. Primary Immune Deficiency (PID) - Therapeutics Development
  4. Primary Immune Deficiency (PID) - Therapeutics Assessment
  5. Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
  6. Primary Immune Deficiency (PID) - Drug Profiles
  7. Primary Immune Deficiency (PID) - Dormant Projects
  8. Primary Immune Deficiency (PID) - Discontinued Products
  9. Primary Immune Deficiency (PID) - Product Development Milestones
  10. Appendix

Companies Mentioned

  • ADMA Biologics Inc
  • Biotest AG
  • GC Pharma
  • GigaGen Inc
  • Novartis AG
  • Octapharma AG
  • Orchard Therapeutics Plc
  • ProMetic Life Sciences Inc
  • Sangamo Therapeutics Inc
  • Taiga Biotechnologies Inc
  • Takeda Pharmaceutical Co Ltd
  • X4 Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kzs3o7

View source version on businesswire.com:https://www.businesswire.com/news/home/20190408005597/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/08/2019 11:30 AM/DISC: 04/08/2019 11:30 AM

http://www.businesswire.com/news/home/20190408005597/en